Browse NKX3-2

Summary
SymbolNKX3-2
NameNK3 homeobox 2
Aliases NKX3B; NKX3.2; BAPX1; bagpipe homeobox homolog 1 (Drosophila); SMMD; bagpipe homeobox protein homolog 1; hom ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00046 Homeobox domain
Function

Transcriptional repressor that acts as a negative regulator of chondrocyte maturation. PLays a role in distal stomach development; required for proper antral-pyloric morphogenesis and development of antral-type epithelium. In concert with GSC, defines the structural components of the middle ear; required for tympanic ring and gonium development and in the regulation of the width of the malleus (By similarity).

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0002062 chondrocyte differentiation
GO:0002064 epithelial cell development
GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0002066 columnar/cuboidal epithelial cell development
GO:0007368 determination of left/right symmetry
GO:0007389 pattern specification process
GO:0007423 sensory organ development
GO:0009799 specification of symmetry
GO:0009855 determination of bilateral symmetry
GO:0031016 pancreas development
GO:0032330 regulation of chondrocyte differentiation
GO:0032331 negative regulation of chondrocyte differentiation
GO:0042471 ear morphogenesis
GO:0042474 middle ear morphogenesis
GO:0043583 ear development
GO:0048536 spleen development
GO:0048562 embryonic organ morphogenesis
GO:0048565 digestive tract development
GO:0048568 embryonic organ development
GO:0048645 animal organ formation
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0051216 cartilage development
GO:0055123 digestive system development
GO:0060575 intestinal epithelial cell differentiation
GO:0060576 intestinal epithelial cell development
GO:0061035 regulation of cartilage development
GO:0061037 negative regulation of cartilage development
GO:0061448 connective tissue development
GO:0090596 sensory organ morphogenesis
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001078 transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolNKX3-2
NameNK3 homeobox 2
Aliases NKX3B; NKX3.2; BAPX1; bagpipe homeobox homolog 1 (Drosophila); SMMD; bagpipe homeobox protein homolog 1; hom ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NKX3-2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNKX3-2
NameNK3 homeobox 2
Aliases NKX3B; NKX3.2; BAPX1; bagpipe homeobox homolog 1 (Drosophila); SMMD; bagpipe homeobox protein homolog 1; hom ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NKX3-2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNKX3-2
NameNK3 homeobox 2
Aliases NKX3B; NKX3.2; BAPX1; bagpipe homeobox homolog 1 (Drosophila); SMMD; bagpipe homeobox protein homolog 1; hom ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NKX3-2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5280.124
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6890.241
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4090.412
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4510.565
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.030.395
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2830.842
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.830.00621
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-3.1850.0011
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2350.838
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0610.901
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2940.677
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0680.765
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NKX3-2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNKX3-2
NameNK3 homeobox 2
Aliases NKX3B; NKX3.2; BAPX1; bagpipe homeobox homolog 1 (Drosophila); SMMD; bagpipe homeobox protein homolog 1; hom ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NKX3-2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNKX3-2
NameNK3 homeobox 2
Aliases NKX3B; NKX3.2; BAPX1; bagpipe homeobox homolog 1 (Drosophila); SMMD; bagpipe homeobox protein homolog 1; hom ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NKX3-2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NKX3-2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNKX3-2
NameNK3 homeobox 2
Aliases NKX3B; NKX3.2; BAPX1; bagpipe homeobox homolog 1 (Drosophila); SMMD; bagpipe homeobox protein homolog 1; hom ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NKX3-2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNKX3-2
NameNK3 homeobox 2
Aliases NKX3B; NKX3.2; BAPX1; bagpipe homeobox homolog 1 (Drosophila); SMMD; bagpipe homeobox protein homolog 1; hom ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NKX3-2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNKX3-2
NameNK3 homeobox 2
Aliases NKX3B; NKX3.2; BAPX1; bagpipe homeobox homolog 1 (Drosophila); SMMD; bagpipe homeobox protein homolog 1; hom ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NKX3-2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNKX3-2
NameNK3 homeobox 2
Aliases NKX3B; NKX3.2; BAPX1; bagpipe homeobox homolog 1 (Drosophila); SMMD; bagpipe homeobox protein homolog 1; hom ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NKX3-2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.